CA2565014A1

CA2565014A1 - Molecules d'acides nucleiques isolees codant une nouvelle phosphoproteine-darpp-32, proteine codee et utilisations associees

Molecules d'acides nucleiques isolees codant une nouvelle phosphoproteine-darpp-32, proteine codee et utilisations associees Download PDF

Info

Publication number: CA2565014A1
Authority: CA; Canada
Prior art keywords: darpp; therapeutic moiety; antibody; seq; dopamine
Prior art date: 2004-05-19
Legal status : Abandoned

Application number

CA002565014A

Other languages

English (en)

Inventor

Philip E. Brandish

Paul J. Acton

Nan Wei

Current Assignee

Merck and Co Inc

Original Assignee

Individual

Priority date

2004-05-19

Filing date

2005-05-17

Publication date

2005-12-01

2005-05-17 Application filed by Individual filed Critical Individual

2005-12-01 Publication of CA2565014A1 publication Critical patent/CA2565014A1/fr

Status Abandoned legal-status Critical Current

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 41
102000039446 nucleic acids Human genes 0.000 title claims abstract description 27
108020004707 nucleic acids Proteins 0.000 title claims abstract description 27
108090000623 proteins and genes Proteins 0.000 title abstract description 111
102000004169 proteins and genes Human genes 0.000 title abstract description 80
108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 claims abstract description 321
102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 claims abstract description 320
238000000034 method Methods 0.000 claims abstract description 172
230000026731 phosphorylation Effects 0.000 claims abstract description 93
238000006366 phosphorylation reaction Methods 0.000 claims abstract description 93
150000001875 compounds Chemical class 0.000 claims abstract description 92
230000031146 intracellular signal transduction Effects 0.000 claims abstract description 53
230000003291 dopaminomimetic effect Effects 0.000 claims abstract description 40
230000001105 regulatory effect Effects 0.000 claims abstract description 34
150000001413 amino acids Chemical group 0.000 claims abstract description 31
102000007982 Phosphoproteins Human genes 0.000 claims abstract description 11
108010089430 Phosphoproteins Proteins 0.000 claims abstract description 11
230000001594 aberrant effect Effects 0.000 claims abstract description 11
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 213
230000001225 therapeutic effect Effects 0.000 claims description 140
230000000694 effects Effects 0.000 claims description 135
229960003638 dopamine Drugs 0.000 claims description 106
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 97
239000012634 fragment Substances 0.000 claims description 84
208000035475 disorder Diseases 0.000 claims description 54
125000003729 nucleotide group Chemical group 0.000 claims description 53
239000002773 nucleotide Substances 0.000 claims description 50
230000030609 dephosphorylation Effects 0.000 claims description 49
238000006209 dephosphorylation reaction Methods 0.000 claims description 49
108090000765 processed proteins & peptides Proteins 0.000 claims description 44
230000014509 gene expression Effects 0.000 claims description 43
125000003275 alpha amino acid group Chemical group 0.000 claims description 37
201000010099 disease Diseases 0.000 claims description 37
238000011282 treatment Methods 0.000 claims description 36
230000027455 binding Effects 0.000 claims description 33
102000004196 processed proteins & peptides Human genes 0.000 claims description 33
230000001404 mediated effect Effects 0.000 claims description 31
108091028043 Nucleic acid sequence Proteins 0.000 claims description 26
230000007423 decrease Effects 0.000 claims description 25
101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims description 24
229920001184 polypeptide Polymers 0.000 claims description 24
241001465754 Metazoa Species 0.000 claims description 17
201000000980 schizophrenia Diseases 0.000 claims description 17
230000000295 complement effect Effects 0.000 claims description 16
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims description 15
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims description 15
229940095074 cyclic amp Drugs 0.000 claims description 15
230000008482 dysregulation Effects 0.000 claims description 15
108090000511 Dopamine D1 Receptors Proteins 0.000 claims description 11
102000004076 Dopamine D1 Receptors Human genes 0.000 claims description 11
230000004068 intracellular signaling Effects 0.000 claims description 11
208000018737 Parkinson disease Diseases 0.000 claims description 10
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
230000002068 genetic effect Effects 0.000 claims description 8
230000004044 response Effects 0.000 claims description 8
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims description 6
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
238000011835 investigation Methods 0.000 claims description 3
229940124606 potential therapeutic agent Drugs 0.000 claims 2
230000009261 transgenic effect Effects 0.000 claims 1
230000019491 signal transduction Effects 0.000 abstract description 28
241000700199 Cavia porcellus Species 0.000 abstract description 14
239000000203 mixture Substances 0.000 abstract description 14
210000004027 cell Anatomy 0.000 description 137
235000018102 proteins Nutrition 0.000 description 75
238000003556 assay Methods 0.000 description 48
238000012360 testing method Methods 0.000 description 39
238000009396 hybridization Methods 0.000 description 31
239000000523 sample Substances 0.000 description 31
235000001014 amino acid Nutrition 0.000 description 30
102000001253 Protein Kinase Human genes 0.000 description 29
229940024606 amino acid Drugs 0.000 description 29
108091033319 polynucleotide Proteins 0.000 description 29
239000002157 polynucleotide Substances 0.000 description 29
102000040430 polynucleotide Human genes 0.000 description 29
108060006633 protein kinase Proteins 0.000 description 29
230000004913 activation Effects 0.000 description 28
210000001519 tissue Anatomy 0.000 description 28
108020004414 DNA Proteins 0.000 description 27
101710118321 Casein kinase I isoform alpha Proteins 0.000 description 26
239000003814 drug Substances 0.000 description 26
238000003752 polymerase chain reaction Methods 0.000 description 26
101000611262 Caenorhabditis elegans Probable protein phosphatase 2C T23F11.1 Proteins 0.000 description 25
101000688229 Leishmania chagasi Protein phosphatase 2C Proteins 0.000 description 25
239000013598 vector Substances 0.000 description 25
229940079593 drug Drugs 0.000 description 24
241000282414 Homo sapiens Species 0.000 description 23
-1 and opiate classes Chemical compound 0.000 description 23
102000005962 receptors Human genes 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
239000000243 solution Substances 0.000 description 23
102000003678 AMPA Receptors Human genes 0.000 description 21
108090000078 AMPA Receptors Proteins 0.000 description 21
208000028017 Psychotic disease Diseases 0.000 description 19
239000002299 complementary DNA Substances 0.000 description 18
239000003112 inhibitor Substances 0.000 description 18
208000024891 symptom Diseases 0.000 description 18
239000013604 expression vector Substances 0.000 description 17
239000000126 substance Substances 0.000 description 17
230000000561 anti-psychotic effect Effects 0.000 description 16
210000002569 neuron Anatomy 0.000 description 16
230000004075 alteration Effects 0.000 description 15
238000004458 analytical method Methods 0.000 description 14
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
238000013456 study Methods 0.000 description 14
108090000312 Calcium Channels Proteins 0.000 description 13
102000003922 Calcium Channels Human genes 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
230000008859 change Effects 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
230000001965 increasing effect Effects 0.000 description 13
238000012216 screening Methods 0.000 description 13
108091026890 Coding region Proteins 0.000 description 12
101000686996 Homo sapiens Protein phosphatase 1 regulatory subunit 1B Proteins 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 12
210000004556 brain Anatomy 0.000 description 12
230000001419 dependent effect Effects 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
239000003693 atypical antipsychotic agent Substances 0.000 description 11
239000008194 pharmaceutical composition Substances 0.000 description 11
230000008569 process Effects 0.000 description 11
230000006870 function Effects 0.000 description 10
102000050953 human PPP1R1B Human genes 0.000 description 10
238000003780 insertion Methods 0.000 description 10
230000037431 insertion Effects 0.000 description 10
230000003834 intracellular effect Effects 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 10
239000007790 solid phase Substances 0.000 description 10
239000000758 substrate Substances 0.000 description 10
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical class [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 9
101710105094 Cyclic AMP-responsive element-binding protein Proteins 0.000 description 9
206010043118 Tardive Dyskinesia Diseases 0.000 description 9
238000007792 addition Methods 0.000 description 9
239000000556 agonist Substances 0.000 description 9
239000005557 antagonist Substances 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
230000002759 chromosomal effect Effects 0.000 description 9
210000000349 chromosome Anatomy 0.000 description 9
108020001507 fusion proteins Proteins 0.000 description 9
102000037865 fusion proteins Human genes 0.000 description 9
238000012163 sequencing technique Methods 0.000 description 9
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
102000005569 Protein Phosphatase 1 Human genes 0.000 description 8
108010059000 Protein Phosphatase 1 Proteins 0.000 description 8
241000700605 Viruses Species 0.000 description 8
230000000692 anti-sense effect Effects 0.000 description 8
229940127236 atypical antipsychotics Drugs 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
239000003550 marker Substances 0.000 description 8
230000000144 pharmacologic effect Effects 0.000 description 8
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 8
239000007787 solid Substances 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
230000014616 translation Effects 0.000 description 8
102000015554 Dopamine receptor Human genes 0.000 description 7
108050004812 Dopamine receptor Proteins 0.000 description 7
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 7
108091000080 Phosphotransferase Proteins 0.000 description 7
230000003321 amplification Effects 0.000 description 7
239000000164 antipsychotic agent Substances 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
238000010367 cloning Methods 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000003993 interaction Effects 0.000 description 7
239000002858 neurotransmitter agent Substances 0.000 description 7
238000003199 nucleic acid amplification method Methods 0.000 description 7
102000020233 phosphotransferase Human genes 0.000 description 7
238000000746 purification Methods 0.000 description 7
230000000862 serotonergic effect Effects 0.000 description 7
229940076279 serotonin Drugs 0.000 description 7
238000013519 translation Methods 0.000 description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
108700028369 Alleles Proteins 0.000 description 6
102000004631 Calcineurin Human genes 0.000 description 6
108010042955 Calcineurin Proteins 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
241000196324 Embryophyta Species 0.000 description 6
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
238000010171 animal model Methods 0.000 description 6
229940005529 antipsychotics Drugs 0.000 description 6
230000033228 biological regulation Effects 0.000 description 6
239000011575 calcium Substances 0.000 description 6
229910052791 calcium Inorganic materials 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000001514 detection method Methods 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
210000001577 neostriatum Anatomy 0.000 description 6
230000001537 neural effect Effects 0.000 description 6
230000037361 pathway Effects 0.000 description 6
238000003118 sandwich ELISA Methods 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
206010001497 Agitation Diseases 0.000 description 5
108020004635 Complementary DNA Proteins 0.000 description 5
102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 5
108090001111 Dopamine D2 Receptors Proteins 0.000 description 5
102000004980 Dopamine D2 Receptors Human genes 0.000 description 5
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
101000686989 Rattus norvegicus Protein phosphatase 1 regulatory subunit 1B Proteins 0.000 description 5
230000009471 action Effects 0.000 description 5
108060000200 adenylate cyclase Proteins 0.000 description 5
102000030621 adenylate cyclase Human genes 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
229910001424 calcium ion Inorganic materials 0.000 description 5
230000003412 degenerative effect Effects 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
229930195712 glutamate Natural products 0.000 description 5
238000005259 measurement Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000003278 mimic effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
230000009822 protein phosphorylation Effects 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
239000011734 sodium Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
208000011117 substance-related disease Diseases 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
108091006112 ATPases Proteins 0.000 description 4
102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
102000008122 Casein Kinase I Human genes 0.000 description 4
108010049812 Casein Kinase I Proteins 0.000 description 4
102000011632 Caseins Human genes 0.000 description 4
108010076119 Caseins Proteins 0.000 description 4
101150053721 Cdk5 gene Proteins 0.000 description 4
108091035707 Consensus sequence Proteins 0.000 description 4
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 4
101150049660 DRD2 gene Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
101100520968 Homo sapiens PPP1R1B gene Proteins 0.000 description 4
108010038807 Oligopeptides Proteins 0.000 description 4
102000015636 Oligopeptides Human genes 0.000 description 4
102100024556 Protein phosphatase 1 regulatory subunit 1B Human genes 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
238000013019 agitation Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000003925 brain function Effects 0.000 description 4
239000005018 casein Substances 0.000 description 4
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
235000021240 caseins Nutrition 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000007850 fluorescent dye Substances 0.000 description 4
238000002509 fluorescent in situ hybridization Methods 0.000 description 4
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
238000013507 mapping Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000003176 neuroleptic agent Substances 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
230000015883 synaptic transmission, dopaminergic Effects 0.000 description 4
CTFDMGIBHFQWKB-UHFFFAOYSA-N 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(N)=N1 CTFDMGIBHFQWKB-UHFFFAOYSA-N 0.000 description 3
PAPYICJQRHSQGK-UHFFFAOYSA-N 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2-ylamine Chemical compound NC1=NC=CC(C2=C(SC(Cl)=C2)Cl)=N1 PAPYICJQRHSQGK-UHFFFAOYSA-N 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
108091093088 Amplicon Proteins 0.000 description 3
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
102000052052 Casein Kinase II Human genes 0.000 description 3
108010010919 Casein Kinase II Proteins 0.000 description 3
108091006146 Channels Proteins 0.000 description 3
108050006400 Cyclin Proteins 0.000 description 3
102000016736 Cyclin Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108010013369 Enteropeptidase Proteins 0.000 description 3
102100029727 Enteropeptidase Human genes 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
102000018899 Glutamate Receptors Human genes 0.000 description 3
108010027915 Glutamate Receptors Proteins 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
208000023105 Huntington disease Diseases 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
101710182846 Polyhedrin Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
102000006478 Protein Phosphatase 2 Human genes 0.000 description 3
108010058956 Protein Phosphatase 2 Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
101000686990 Sus scrofa Protein phosphatase 1 regulatory subunit 1B Proteins 0.000 description 3
241000723873 Tobacco mosaic virus Species 0.000 description 3
208000000323 Tourette Syndrome Diseases 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000012190 activator Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000001106 artificial yeast chromosome Anatomy 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000012875 competitive assay Methods 0.000 description 3
230000009918 complex formation Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000003210 dopamine receptor blocking agent Substances 0.000 description 3
230000010249 dopaminergic function Effects 0.000 description 3
229940000406 drug candidate Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000007877 drug screening Methods 0.000 description 3
239000000975 dye Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000007901 in situ hybridization Methods 0.000 description 3
238000005462 in vivo assay Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
230000002452 interceptive effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000007310 pathophysiology Effects 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000006104 solid solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
201000009032 substance abuse Diseases 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
102000000584 Calmodulin Human genes 0.000 description 2
108010041952 Calmodulin Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 2
108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 2
102100030013 Endoribonuclease Human genes 0.000 description 2
101710199605 Endoribonuclease Proteins 0.000 description 2
208000027776 Extrapyramidal disease Diseases 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
108010074860 Factor Xa Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
208000019022 Mood disease Diseases 0.000 description 2
101000686995 Mus musculus Protein phosphatase 1 regulatory subunit 1B Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010067902 Peptide Library Proteins 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010047313 Protein phosphatase 2C Proteins 0.000 description 2
102000006831 Protein phosphatase 2C Human genes 0.000 description 2
108020004518 RNA Probes Proteins 0.000 description 2
239000003391 RNA probe Substances 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
241000255985 Trichoplusia Species 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940025084 amphetamine Drugs 0.000 description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
238000005251 capillar electrophoresis Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
229960004170 clozapine Drugs 0.000 description 2
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
229960003920 cocaine Drugs 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 2
229940052760 dopamine agonists Drugs 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
238000007878 drug screening assay Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000003269 fluorescent indicator Substances 0.000 description 2
108091006047 fluorescent proteins Proteins 0.000 description 2
102000034287 fluorescent proteins Human genes 0.000 description 2
238000009472 formulation Methods 0.000 description 2
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
229960003878 haloperidol Drugs 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
210000003917 human chromosome Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000031864 metaphase Effects 0.000 description 2
238000001823 molecular biology technique Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000001095 motoneuron effect Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000035939 shock Effects 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
108010088556 tau protein kinase II Proteins 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
229960004441 tyrosine Drugs 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
238000005406 washing Methods 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
AADCDMQTJNYOSS-LBPRGKRZSA-N 5-chloro-3-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(CC)=CC(Cl)=C1OC AADCDMQTJNYOSS-LBPRGKRZSA-N 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010025188 Alcohol oxidase Proteins 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
206010002820 Antisocial behaviour Diseases 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006100 Bradykinesia Diseases 0.000 description 1
206010050012 Bradyphrenia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
108091007914 CDKs Proteins 0.000 description 1
229940122642 Calcium channel agonist Drugs 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
102100024318 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Human genes 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
239000005496 Chlorsulfuron Substances 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
101710133745 Cyclin-dependent-like kinase 5 Proteins 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
206010054089 Depressive symptom Diseases 0.000 description 1
108091007265 Dopamine D2-Like Receptors Proteins 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101001117099 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Proteins 0.000 description 1
101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
108010083687 Ion Pumps Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
101710200582 Major spike protein G Proteins 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241000204795 Muraena helena Species 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
108010050574 NR1 NMDA receptor Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101710143098 Paralytic peptide 1 Proteins 0.000 description 1
206010033864 Paranoia Diseases 0.000 description 1
208000027099 Paranoid disease Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
206010036467 Poverty of speech Diseases 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108010065868 RNA polymerase SP6 Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
101710189648 Serine/threonine-protein phosphatase Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
206010041243 Social avoidant behaviour Diseases 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010048327 Supranuclear palsy Diseases 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
102000002933 Thioredoxin Human genes 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
238000012197 amplification kit Methods 0.000 description 1
239000012491 analyte Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
229930002877 anthocyanin Natural products 0.000 description 1
235000010208 anthocyanin Nutrition 0.000 description 1
239000004410 anthocyanin Substances 0.000 description 1
150000004636 anthocyanins Chemical class 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000002932 anti-schizophrenic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940125688 antiparkinson agent Drugs 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
208000024823 antisocial personality disease Diseases 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
239000000823 artificial membrane Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
230000006399 behavior Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
238000005460 biophysical method Methods 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000009111 cAMP-PKA pathway Effects 0.000 description 1
150000001669 calcium Chemical class 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000000801 calcium channel stimulating agent Substances 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
238000003200 chromosome mapping Methods 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000009510 drug design Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000002049 efferent pathway Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
229950007535 eticlopride Drugs 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
230000004907 flux Effects 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000002306 glutamic acid derivatives Chemical class 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000002363 herbicidal effect Effects 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
101150113423 hisD gene Proteins 0.000 description 1
230000000742 histaminergic effect Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
102000057063 human MAPT Human genes 0.000 description 1
210000000688 human artificial chromosome Anatomy 0.000 description 1
229960003162 iloperidone Drugs 0.000 description 1
XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000013198 immunometric assay Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000006662 intracellular pathway Effects 0.000 description 1
238000007852 inverse PCR Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000001730 monoaminergic effect Effects 0.000 description 1
230000007659 motor function Effects 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000008587 neuronal excitability Effects 0.000 description 1
230000034420 neuronal signal transduction Effects 0.000 description 1
230000009994 neurotransmitter pathway Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
230000031787 nutrient reservoir activity Effects 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229950004193 perospirone Drugs 0.000 description 1
GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
238000011020 pilot scale process Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
210000002442 prefrontal cortex Anatomy 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
210000001176 projection neuron Anatomy 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001915 proofreading effect Effects 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
210000004777 protein coat Anatomy 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
239000003196 psychodysleptic agent Substances 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960001534 risperidone Drugs 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
238000002821 scintillation proximity assay Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
208000016686 tic disease Diseases 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
101150081616 trpB gene Proteins 0.000 description 1
101150111232 trpB-1 gene Proteins 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229960000607 ziprasidone Drugs 0.000 description 1
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
229960004496 zotepine Drugs 0.000 description 1
HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1